Glucocorticoid therapy and ocular hypertension

Adnan Dibas, Thomas Yorio

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

The projected number of people who will develop age-related macular degeneration in estimated at 2020 is 196 million and is expected to reach 288 million in 2040. Also, the number of people with Diabetic retinopathy will grow from 126.6 million in 2010 to 191.0 million by 2030. In addition, it is estimated that there are 2.3 million people suffering from uveitis worldwide. Because of the anti-inflammatory properties of glucocorticoids (GCs), they are often used topically and/or intravitreally to treat ocular inflammation conditions or edema associated with macular degeneration and diabetic retinopathy. Unfortunately, ocular GC therapy can lead to severe side effects. Serious and sometimes irreversible eye damage can occur as a result of the development of GC-induced ocular hypertension causing secondary open-angle glaucoma. According to the world health organization, glaucoma is the second leading cause of blindness in the world and it is estimated that 80 million will suffer from glaucoma by 2020. In the current review, mechanisms of GC-induced damage in ocular tissue, GC-resistance, and enhancing GC therapy will be discussed.

Original languageEnglish
Pages (from-to)57-71
Number of pages15
JournalEuropean Journal of Pharmacology
Volume787
DOIs
StatePublished - 1 Jan 2016

Fingerprint

Ocular Hypertension
Glucocorticoids
Macular Degeneration
Diabetic Retinopathy
Glaucoma
Therapeutics
Open Angle Glaucoma
Uveitis
Blindness
Edema
Anti-Inflammatory Agents
Inflammation

Keywords

  • Glaucoma
  • Glucocorticoids
  • Steroid receptors
  • Trabecular meshwork

Cite this

@article{a816fedd53d848f7b4393584accd5d1d,
title = "Glucocorticoid therapy and ocular hypertension",
abstract = "The projected number of people who will develop age-related macular degeneration in estimated at 2020 is 196 million and is expected to reach 288 million in 2040. Also, the number of people with Diabetic retinopathy will grow from 126.6 million in 2010 to 191.0 million by 2030. In addition, it is estimated that there are 2.3 million people suffering from uveitis worldwide. Because of the anti-inflammatory properties of glucocorticoids (GCs), they are often used topically and/or intravitreally to treat ocular inflammation conditions or edema associated with macular degeneration and diabetic retinopathy. Unfortunately, ocular GC therapy can lead to severe side effects. Serious and sometimes irreversible eye damage can occur as a result of the development of GC-induced ocular hypertension causing secondary open-angle glaucoma. According to the world health organization, glaucoma is the second leading cause of blindness in the world and it is estimated that 80 million will suffer from glaucoma by 2020. In the current review, mechanisms of GC-induced damage in ocular tissue, GC-resistance, and enhancing GC therapy will be discussed.",
keywords = "Glaucoma, Glucocorticoids, Steroid receptors, Trabecular meshwork",
author = "Adnan Dibas and Thomas Yorio",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejphar.2016.06.018",
language = "English",
volume = "787",
pages = "57--71",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

Glucocorticoid therapy and ocular hypertension. / Dibas, Adnan; Yorio, Thomas.

In: European Journal of Pharmacology, Vol. 787, 01.01.2016, p. 57-71.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Glucocorticoid therapy and ocular hypertension

AU - Dibas, Adnan

AU - Yorio, Thomas

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The projected number of people who will develop age-related macular degeneration in estimated at 2020 is 196 million and is expected to reach 288 million in 2040. Also, the number of people with Diabetic retinopathy will grow from 126.6 million in 2010 to 191.0 million by 2030. In addition, it is estimated that there are 2.3 million people suffering from uveitis worldwide. Because of the anti-inflammatory properties of glucocorticoids (GCs), they are often used topically and/or intravitreally to treat ocular inflammation conditions or edema associated with macular degeneration and diabetic retinopathy. Unfortunately, ocular GC therapy can lead to severe side effects. Serious and sometimes irreversible eye damage can occur as a result of the development of GC-induced ocular hypertension causing secondary open-angle glaucoma. According to the world health organization, glaucoma is the second leading cause of blindness in the world and it is estimated that 80 million will suffer from glaucoma by 2020. In the current review, mechanisms of GC-induced damage in ocular tissue, GC-resistance, and enhancing GC therapy will be discussed.

AB - The projected number of people who will develop age-related macular degeneration in estimated at 2020 is 196 million and is expected to reach 288 million in 2040. Also, the number of people with Diabetic retinopathy will grow from 126.6 million in 2010 to 191.0 million by 2030. In addition, it is estimated that there are 2.3 million people suffering from uveitis worldwide. Because of the anti-inflammatory properties of glucocorticoids (GCs), they are often used topically and/or intravitreally to treat ocular inflammation conditions or edema associated with macular degeneration and diabetic retinopathy. Unfortunately, ocular GC therapy can lead to severe side effects. Serious and sometimes irreversible eye damage can occur as a result of the development of GC-induced ocular hypertension causing secondary open-angle glaucoma. According to the world health organization, glaucoma is the second leading cause of blindness in the world and it is estimated that 80 million will suffer from glaucoma by 2020. In the current review, mechanisms of GC-induced damage in ocular tissue, GC-resistance, and enhancing GC therapy will be discussed.

KW - Glaucoma

KW - Glucocorticoids

KW - Steroid receptors

KW - Trabecular meshwork

UR - http://www.scopus.com/inward/record.url?scp=84978898122&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.06.018

DO - 10.1016/j.ejphar.2016.06.018

M3 - Article

VL - 787

SP - 57

EP - 71

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -